MedPage Today July 5, 2024
— For people with diabetes, cancer risks were reduced with GLP-1s versus insulin
GLP-1 receptor agonists lowered the risk of several obesity-associated cancers, a retrospective analysis of electronic health records suggested.
Compared with insulin, GLP-1s were associated with a lower risk for developing 10 of 13 cancers in people with type II diabetes, reported Nathan Berger, MD, of the Case Western Reserve University in Cleveland, and colleagues in JAMA Network Open.
The follow-up period spanned up to 15 years, and showed risk reductions for:
- Gallbladder cancer: HR 0.35 (95% CI 0.15-0.83)
- Meningioma: HR 0.37 (95% CI 0.18-0.74)
- Pancreatic cancer: HR 0.41 (95% CI 0.33-0.50)
- Hepatocellular carcinoma: HR 0.47 (95% CI 0.36-0.61)
- Ovarian cancer: HR 0.52 (95% CI 0.37-0.74)
- Colorectal...
Today's Sponsors
Today's Sponsor